Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Konstantin Byrgazov"'
Autor:
Mathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Chantal Blanche Lucini, Susanne Herndlhofer, Sandra Preuner, Klara Obrova, Petra Pusic, Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Wolfgang R. Sperr, Thomas Lion, Michael Deininger, Peter Valent, Karoline V. Gleixner
Publikováno v:
EBioMedicine, Vol 50, Iss , Pp 111-121 (2019)
Purpose: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1T315I-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1T315I-mutated CML remains a clinical challenge. Hy
Externí odkaz:
https://doaj.org/article/fbb9dd16496d4e52a309a4b4f40496e3
Autor:
Konstantin Byrgazov, Thomas Lind, Annica J. Rasmusson, Claes Andersson, Ana Slipicevic, Fredrik Lehmann, Joachim Gullbo, Håkan Melhus, Rolf Larsson, Mårten Fryknäs
Publikováno v:
Bone Reports, Vol 15, Iss , Pp 101098- (2021)
Myeloma bone disease is a major complication in multiple myeloma affecting quality of life and survival. It is characterized by increased activity of osteoclasts, bone resorbing cells. Myeloma microenvironment promotes excessive osteoclastogenesis, a
Externí odkaz:
https://doaj.org/article/cd014e14ebe249af86995086ee1a9c0e
Autor:
Konstantin Byrgazov, Andrej Besse, Marianne Kraus, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, Lenka Besse
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e602 (2021)
Introduction of the proteasome inhibitor bortezomib has dramatically improved clinical outcomes in multiple myeloma. However, most patients become refractory to bortezomib-based therapies. On the molecular level, development of resistance to bortezom
Externí odkaz:
https://doaj.org/article/5b74bd320c2440168f319eecd0ee0e6a
Autor:
Konstantin Byrgazov, Claes Anderson, Benjamin Salzer, Eva Bozsaky, Rolf Larsson, Joachim Gullbo, Manfred Lehner, Fredrik Lehmann, Ana Slipicevic, Leo Kager, Mårten Fryknäs, Sabine Taschner-Mandl
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Low survival rates in metastatic high-grade osteosarcoma (HGOS) have remained stagnant for the last three decades. This study aims to investigate the role of aminopeptidase N (ANPEP) in HGOS progression and its targeting with a novel lipo
Externí odkaz:
https://doaj.org/article/17f19891afa74cb9b7cb91bdd80f702b
Publikováno v:
Haematologica, Vol 103, Iss 1 (2018)
Externí odkaz:
https://doaj.org/article/73c25cc4f7374b0eb21c9fe98ff6923a
Autor:
Karoline V. Gleixner, Mathias Schneeweiss, Gregor Eisenwort, Daniela Berger, Harald Herrmann, Katharina Blatt, Georg Greiner, Konstantin Byrgazov, Gregor Hoermann, Marina Konopleva, Islam Waliul, Abbarna A. Cumaraswamy, Patrick T. Gunning, Hiroshi Maeda, Richard Moriggl, Michael Deininger, Thomas Lion, Michael Andreeff, Peter Valent
Publikováno v:
Haematologica, Vol 102, Iss 9 (2017)
In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of BCR-ABL1 mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. Drug combinations covering a broad range of targ
Externí odkaz:
https://doaj.org/article/d343352f0bfb410bb4f4b484b265465c
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32702 (2012)
Despite of the high resolution structure available for the E. coli ribosome, hitherto the structure and localization of the essential ribosomal protein S1 on the 30 S subunit still remains to be elucidated. It was previously reported that protein S1
Externí odkaz:
https://doaj.org/article/d352ba480d6f4547820c920bdb727f89
Autor:
Andrej Besse, Marianne Kraus, Christoph Driessen, Lenka Besse, Ana Slipicevic, Konstantin Byrgazov, Fredrik Lehmann
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e602 (2021)
HemaSphere
HemaSphere
Introduction of the proteasome inhibitor bortezomib has dramatically improved clinical outcomes in multiple myeloma. However, most patients become refractory to bortezomib-based therapies. On the molecular level, development of resistance to bortezom
Autor:
Fredrik Lehmann, Annica J. Rasmusson, Mårten Fryknäs, Ana Slipicevic, Claes Andersson, Håkan Melhus, Thomas Lind, Rolf Larsson, Joachim Gullbo, Konstantin Byrgazov
Publikováno v:
Bone Reports
Bone Reports, Vol 15, Iss, Pp 101098-(2021)
Bone Reports, Vol 15, Iss, Pp 101098-(2021)
Myeloma bone disease is a major complication in multiple myeloma affecting quality of life and survival. It is characterized by increased activity of osteoclasts, bone resorbing cells. Myeloma microenvironment promotes excessive osteoclastogenesis, a
Autor:
Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Irina Sadovnik, Karoline V. Gleixner, Mathias Schneeweiss, Harald Herrmann, Peter Valent, Emir Hadzijusufovic, Thomas Lion, Konstantin Byrgazov
Publikováno v:
Leukemia Research. 78:36-44
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in the context of multi-resistant BCR-ABL1 mutants, such as T315I. Treatment with ponatinib may